Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kitahara, M.
Right arrow Articles by Floege, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kitahara, M.
Right arrow Articles by Floege, J.
J Am Soc Nephrol 13:1261-1270, 2002
© 2002 American Society of Nephrology

Selective Cyclooxygenase-2 Inhibition Impairs Glomerular Capillary Healing in Experimental Glomerulonephritis

Masashi Kitahara*, Frank Eitner*, Tammo Ostendorf*, Uta Kunter*, Ulf Janssen*, Ralf Westenfeld*, Katsuyuki Matsui{dagger}, Dontscho Kerjaschki{dagger} and Jürgen Floege*

*Division of Nephrology and Immunology, University of Aachen, Aachen, Germany, and {dagger} Department of Pathology, University of Vienna, Vienna, Austria.

Correspondence to Dr. Jürgen Floege, Medizinische Klinik II, Klinikum der RWTH, Pauwelsstrasse 30, D-52074 Aachen, Germany. Phone: 01149-241-8089-530; Fax: 01149-241-8082-446; E-mail: Juergen.Floege{at}post.rwth-aachen.de

ABSTRACT. Selective cyclooxygenase-2 (COX-2) inhibitors have anti-inflammatory activity and reduce proteinuria in experimental membranous glomerulonephritis. Antiangiogenic properties of COX-2 inhibitors were recently reported. Whether these properties are relevant to the glomerular healing process in inflammatory glomerular diseases was investigated. For evaluation of the effects of selective COX-2 inhibitors on the glomerular healing process in a rat model of mesangioproliferative glomerulonephritis (induced by anti-Thy 1.1 antibody), a selective COX-2 inhibitor (rofecoxib or celecoxib) or vehicle was administered daily from day 1 after disease induction until euthanasia on day 6. Additional nephritic rats were treated with rofecoxib or vehicle from day 1 to day 10 and were monitored until day 28. Selective COX-2 inhibition led to significant increases in mesangiolysis (up to +71%) on days 2 and 6 and in albuminuria (up to 3.1-fold) on day 6. This augmentation of glomerular capillary damage was associated with rarefaction of glomerular endothelial cells, whereas the proliferation and activation of mesangial cells were not affected. No significant effects on the glomerular influx of polymorphonuclear neutrophils or the infiltration and proliferation of monocytes/macrophages at day 2 were noted. These effects were independent of systemic hemodynamic features, because rofecoxib did not affect systolic BP on day 2 or 5. Nephritic rats treated with rofecoxib for 10 d demonstrated persistent glomerular injury at day 28, as indicated by increased albuminuria (10-fold) and mesangial type IV collagen deposition (+24%). In normal rats, 5-d administration of rofecoxib failed to induce albuminuria or morphologic renal damage. In conclusion, selective COX-2 inhibitors impair glomerular capillary repair after mesangiolysis in rats with anti-Thy 1.1 glomerulonephritis. These data suggest that selective COX-2 inhibitors should be used with caution among patients with inflammatory endocapillary glomerular disorders.




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
P. Michielsen, L. Heinemann, M. Mihatsch, P. Schnulle, H. Graf, and K.-M. Koch
Non-phenacetin analgesics and analgesic nephropathy: Clinical assessment of high users from a case-control study [
Nephrol. Dial. Transplant., November 26, 2008; (2008) gfn643v1.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
H. Li, M. Hortmann, A. Daiber, M. Oelze, M. A. Ostad, P. M. Schwarz, H. Xu, N. Xia, A. L. Kleschyov, C. Mang, et al.
Cyclooxygenase 2-Selective and Nonselective Nonsteroidal Anti-Inflammatory Drugs Induce Oxidative Stress by Up-Regulating Vascular NADPH Oxidases
J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 745 - 753.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
D. Sankaran, N. Bankovic-Calic, M. R. Ogborn, G. Crow, and H. M. Aukema
Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han:SPRD-cy rats with inherited kidney disease
Am J Physiol Renal Physiol, September 1, 2007; 293(3): F821 - F830.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
L. Warford-Woolgar, C. Y.-C. Peng, J. Shuhyta, A. Wakefield, D. Sankaran, M. Ogborn, and H. M. Aukema
Selectivity of cyclooxygenase isoform activity and prostanoid production in normal and diseased Han:SPRD-cy rat kidneys
Am J Physiol Renal Physiol, April 1, 2006; 290(4): F897 - F904.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
T. Ostendorf, C. van Roeyen, R. Westenfeld, A. Gawlik, M. Kitahara, E. de Heer, D. Kerjaschki, J. Floege, and M. Ketteler
Inducible Nitric Oxide Synthase-Derived Nitric Oxide Promotes Glomerular Angiogenesis via Upregulation of Vascular Endothelial Growth Factor Receptors
J. Am. Soc. Nephrol., September 1, 2004; 15(9): 2307 - 2319.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
T. D. WARNER and J. A. MITCHELL
Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic
FASEB J, May 1, 2004; 18(7): 790 - 804.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
C Waldner, K Schror, and P Heering
COX-2 dependent PGE2 downregulates {alpha}v integrin expression via the EP3 receptor in cultured mesangial cells
J. Clin. Pathol., May 1, 2004; 57(5): 553 - 555.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Hermann, G. Camici, A. Fratton, D. Hurlimann, F. C. Tanner, J. P. Hellermann, M. Fiedler, J. Thiery, M. Neidhart, R. E. Gay, et al.
Differential Effects of Selective Cyclooxygenase-2 Inhibitors on Endothelial Function in Salt-Induced Hypertension
Circulation, November 11, 2003; 108(19): 2308 - 2311.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
T. Ostendorf, C. R.C. van Roeyen, J. D. Peterson, U. Kunter, F. Eitner, A. J. Hamad, G. Chan, X.-C. Jia, J. Macaluso, G. Gazit-Bornstein, et al.
A Fully Human Monoclonal Antibody (CR002) Identifies PDGF-D as a Novel Mediator of Mesangioproliferative Glomerulonephritis
J. Am. Soc. Nephrol., September 1, 2003; 14(9): 2237 - 2247.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
V. Campean, F. Theilig, A. Paliege, M. Breyer, and S. Bachmann
Key enzymes for renal prostaglandin synthesis: site-specific expression in rodent kidney (rat, mouse)
Am J Physiol Renal Physiol, July 1, 2003; 285(1): F19 - F32.
[Abstract] [Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP